Research programme: antiemetic therapeutics - InnoPharma

Drug Profile

Research programme: antiemetic therapeutics - InnoPharma

Alternative Names: IP-123

Latest Information Update: 30 Sep 2014

Price : $50

At a glance

  • Originator InnoPharma Inc
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Nausea and vomiting

Most Recent Events

  • 25 Sep 2014 InnoPharma Inc has been acquired by Pfizer
  • 21 Jul 2014 Preclinical development is ongoing in USA
  • 01 Dec 2011 Preclinical trials in Nausea and vomiting in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top